Parkinson's Disease - Roche BN44715

Parkinson’s Disease – Roche BN44715

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson’s disease (PD) on stable symptomatic monotherapy with levodopa.

Inclusion Criteria:

Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2
Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
Has received monotherapy treatment
An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
Hoehn and Yahr (H&Y) Stage 1 or 2 off medication at screening and prior to randomization
Agreement to adhere to the contraception requirements
Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

I am a...

First Name(Required)

Last Name(Required)

Location(Required)

Phone(Required)

Email(Required)

Gender

Conditions

Race

Contact Preference

This field is hidden when viewing the form

Trial (Origination Page)

This field is hidden when viewing the form

UTM Source

This field is hidden when viewing the form

UTM Medium

This field is hidden when viewing the form

UTM Campaign

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone(Required)

Zip Code(Required)

What is the best way to contact you?(Required)

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

This field is hidden when viewing the form

Origination Page

Parkinson’s Disease – Roche BN44715

Trial Interest Form

Locations

Southern California Neurology Consultants

Acne
Advanced/Metastic Non-Small Cell Lung Cancer
Alzheimer’s Disease
Atopic Dermatitis
Breast Cancer
Chronic Heart Failure
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Chronic Obstructive Pulmonary Disease (COPD)
Coronavirus
Eczema
Epilepsy
Flu
Graves
GUILLAIN BARRE SYNDROME
Heart Failure
Hypothyroidism
Immune Thrombocytopenic Purpura (ITP)
Influenza
Influenza Vaccine
Lung Cancer
Multiple Myeloma
Multiple Sclerosis
Multiple Sclerosis Relapse
Myasthenia Gravis
Non-Small Cell Lung Cancer
Osteoarthritis
Parkinson's Disease
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary Immune Thrombocytopenia (ITP)
Prurigo Nodularis
PULMONARY EMBOLISM
Refractory Angina Pectoris
Refractory Focal Onset Epilepsy
Seizures
Solid Tumors
Sytemic Lupus Erythematosus
Type 1 Diabetes
Warm Autoimmune Hemolytic Anemia (wAIHA)